Abstract
Six patients with locally advanced colorectal cancer (including 5 cases of rectal cancer and 1 case of sigmoid colon cancer) were treated with a new neoadjuvant chemotherapy using either mFOLFOX6 plus bevacizumab, or SOX plus bevacizumab. No preoperative radiotherapy was applied in any of the cases. All six patients showed good tumor regression, which facilitated tumor resection in the limited pelvic space. Of the 6 patients, R0 resection was accomplished successfully with no local relapse in 5 patients, while the sixth patient developed invasion of the urinary bladder. Furthermore, 2 patients showed a pathological complete response (pCR) or near-pCR. Grade 3 adverse events occurred during the chemotherapy in 3 patients, including neutropenia in 2 patients and liver dysfunction in 1 patient. Anastomotic leakage occurred in 1 patient after the surgery due to a technical error. This new neoadjuvant chemotherapy without radiotherapy appears promising as a viable treatment strategy for locally advanced colorectal cancer.
